Incannex Healthcare stock tumbles after filing $100M offering
HONG KONG/SINGAPORE - Prudential (LON:PRU) plc has announced the issuance of 22,134 new ordinary shares as part of its scrip dividend alternative, which allows shareholders to receive dividends in the form of additional shares rather than cash. This option, offered under the Evergreen Scrip Dividend Scheme, pertains to the 2024 second interim dividend of 16.29 US cents per ordinary share.
Shareholders who held a minimum of 67 ordinary shares as of the record date, March 28, 2025, are eligible to participate. The new shares will be listed on the Hong Kong line only, with 17,159 of these shares being made available to UK shareholders through a share dealing facility. This facility accommodates those unable to provide a Hong Kong address or brokerage account details, which are necessary for holding shares on the Hong Kong line.
The company has stated that the newly issued shares will rank equally with the existing ordinary shares. Prudential also plans to neutralize any minor dilution to shareholders from the scrip issuance by buying back shares on the London Stock Exchange (LON:LSEG), consistent with the Board’s policy on scrip and staff incentive scheme share issuances.
Prudential plc, with dual primary listings on the Hong Kong and London stock exchanges, is a provider of life and health insurance and asset management services across Asia and Africa. The company emphasizes its commitment to trust and protection across generations by offering accessible financial and health solutions.
The news of the share issuance follows the company’s established procedure for scrip dividends, as detailed in the Evergreen Scrip Dividend Scheme Terms and Conditions. Further announcements regarding the listing and admission of the new shares are expected in due course.
This financial update is based on a press release statement distributed by RNS, the news service of the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.